SENSIENT TECHNOLOGIES CORP — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that SENSIENT TECHNOLOGIES CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Dec 31, 2017 | $1.40B | Feb 23, 2018 |
| FY2016 | Dec 31, 2016 | $1.42B | Feb 23, 2017 |
| FY2015 | Dec 31, 2015 | $1.42B | Feb 25, 2016 |
| FY2014 | Dec 31, 2014 | $1.50B | Feb 26, 2015 |
| FY2013 | Dec 31, 2013 | $1.53B | Feb 28, 2014 |
| FY2013 | Dec 31, 2012 | $1.52B | Feb 28, 2014 |
| FY2013 | Dec 31, 2011 | $1.49B | Feb 28, 2014 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.61B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.56B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $1.46B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.44B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.38B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.33B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.32B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $1.39B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.36B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.38B | Feb 25, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $134.49M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $124.67M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $93.39M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $140.89M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $118.75M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $109.47M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $82.05M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $157.36M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $89.60M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $126.26M | Feb 25, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $207.13M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $191.58M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $155.02M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $196.75M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $170.03M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $152.66M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $121.11M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $203.38M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $167.81M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $185.61M | Feb 25, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $52.90M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $49.10M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $48.10M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $42.20M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $34.30M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $38.50M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $40.10M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $43.00M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $40.90M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $40.90M | Feb 25, 2019 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $332.17M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $315.51M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $305.27M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $292.36M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $284.63M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $271.09M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $293.76M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $262.75M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $307.68M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $289.82M | Feb 25, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $127.83M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $157.15M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $169.70M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $12.07M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $145.22M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $218.78M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $177.18M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $83.52M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $36.31M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $183.64M | Feb 25, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $89.41M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $59.21M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $87.87M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $79.32M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $60.79M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $52.16M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $39.10M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $50.74M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $56.34M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $81.22M | Feb 25, 2019 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.24B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $2.02B | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $2.01B | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $1.98B | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $1.75B | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $1.74B | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $1.74B | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $1.82B | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $1.72B | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $1.67B | Feb 25, 2019 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.19B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.06B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.05B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $999.60M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $938.43M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $934.34M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $881.59M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $859.95M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $852.30M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $835.74M | Feb 23, 2018 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $439.71M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $411.78M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $424.07M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $415.72M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $420.03M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $423.29M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $407.04M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $416.18M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $409.00M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $383.57M | Feb 25, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $1.85B | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $1.78B | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $1.73B | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $1.70B | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $1.63B | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $1.58B | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $1.54B | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $1.52B | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $1.41B | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $1.38B | Feb 23, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $36.53M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $26.63M | Feb 13, 2026 |
| FY2024 | Dec 31, 2023 | $28.93M | Feb 19, 2025 |
| FY2023 | Dec 31, 2022 | $20.92M | Feb 22, 2024 |
| FY2022 | Dec 31, 2021 | $25.74M | Feb 17, 2023 |
| FY2021 | Dec 31, 2020 | $24.77M | Feb 18, 2022 |
| FY2020 | Dec 31, 2019 | $21.15M | Feb 22, 2021 |
| FY2019 | Dec 31, 2018 | $31.90M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $29.34M | Feb 25, 2019 |
| FY2018 | Dec 31, 2016 | $25.87M | Feb 25, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $709.23M | Feb 13, 2026 |
| FY2024 | Dec 31, 2024 | $613.52M | Feb 19, 2025 |
| FY2023 | Dec 31, 2023 | $645.09M | Feb 22, 2024 |
| FY2019 | Dec 31, 2019 | $598.67M | Feb 21, 2020 |
| FY2019 | Dec 31, 2018 | $689.78M | Feb 21, 2020 |
| FY2018 | Dec 31, 2017 | $604.37M | Feb 25, 2019 |
| FY2017 | Dec 31, 2016 | $583.03M | Feb 23, 2018 |
| FY2016 | Dec 31, 2015 | $613.88M | Feb 23, 2017 |
| FY2015 | Dec 31, 2014 | $451.01M | Feb 25, 2016 |
| FY2014 | Dec 31, 2013 | $348.12M | Feb 26, 2015 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 3 | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 25, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3 | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | 2 | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | 2 | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | 3 | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | 2 | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | 2 | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | 1 | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | 3 | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | 2 | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | 2 | Feb 25, 2019 |
Dividends Paid
Cash dividends distributed to common shareholders during the period. Shown as a positive value despite being a cash outflow in the SEC filing.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $69.61M | Feb 13, 2026 |
| FY2025 | Dec 31, 2024 | $69.40M | Feb 13, 2026 |
| FY2025 | Dec 31, 2023 | $69.22M | Feb 13, 2026 |
| FY2024 | Dec 31, 2022 | $68.92M | Feb 19, 2025 |
| FY2023 | Dec 31, 2021 | $66.69M | Feb 22, 2024 |
| FY2022 | Dec 31, 2020 | $66.06M | Feb 17, 2023 |
| FY2021 | Dec 31, 2019 | $62.19M | Feb 18, 2022 |
| FY2020 | Dec 31, 2018 | $57.41M | Feb 22, 2021 |
| FY2019 | Dec 31, 2017 | $54.04M | Feb 21, 2020 |
| FY2018 | Dec 31, 2016 | $49.64M | Feb 25, 2019 |